Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.

Pharmacology, Hôpital Cochin-Saint Vincent de Paul, 82, avenue Denfert Rochereau, 75674 Paris Cedex 14, France.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 12/2004; 48(11):4332-6. DOI: 10.1128/AAC.48.11.4332-4336.2004
Source: PubMed

ABSTRACT This study was performed to investigate placental transfer of nucleoside analogue reverse transcriptase inhibitors (NRTIs) and their concentrations in amniotic fluid when given to human immunodeficiency virus (HIV)-infected pregnant women. A total of 100 HIV type 1-infected mothers receiving antiretroviral therapy, including one or more NRTIs, for clinical indications at the time of delivery were enrolled. Maternal blood samples and amniotic fluid were obtained during delivery or cesarean section, and paired cord blood samples were obtained by venipuncture immediately after delivery. Drug concentrations were measured by using high-performance liquid chromatography. A significant relationship between concentrations in maternal and cord plasma samples was found for zidovudine, lamivudine, stavudine, and didanosine. The ratio between the concentrations in cord and maternal plasma samples (R) was high for zidovudine (R = 1.22), its glucuronide metabolite (3'-azido-3'-deoxythymidine-beta-d-glucuronide) (R = 1.01), stavudine (R = 1.32), lamivudine (R = 0.93), and abacavir (R = 1.03) and was low for didanosine (R = 0.38). The ratio between the concentrations in amniotic fluid and cord plasma samples was high for zidovudine (R = 2.24), its glucuronide metabolite (R = 2.83), stavudine (R = 4.87), and lamivudine (R = 3.99) and was lower for didanosine (R = 1.14). These findings indicate that most NRTIs cross the placenta by simple diffusion and are concentrated in the amniotic fluid, probably through fetal urinary excretion. The efficacy or toxicity of NRTIs may vary according to placental transfer.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this study were to describe the pharmacokinetics of zidovudine (ZDV) and its biotransformation to its metabolite, 3*-azido-3*-deoxy-5*-glucuronylthymidine (G-ZDV), in HIV-infected children, to identify factors that influence the pharmacokinetics of ZDV, and to compare and evaluate the doses recommended by the World Health Organization (WHO) and the Food and Drug Administration (FDA). ZDV concentrations in 782 samples and G-ZDV concentrations in 554 samples from 247 children ranging in age from 0.5 to 18 years were retrospectively measured. A population pharmacokinetic model was developed with NONMEM software (version 6.2), and the pharmacokinetics of ZDV were best described by a one-compartment model with first-order absorption and elimination. The effect of body weight on the apparent elimination clearance and volume of distribution was significant. The mean population parameter estimates were as follows: absorption rate, 2.86 h−1; apparent elimination clearance, 89.7 liters · h−1 (between-subject variability, 0.701 liters · h−1); apparent volume of distribution, 229 liters (between-subject variability, 0.807 liters); metabolic formation rate constant, 12.6 h−1 (between-subject variability, 0.352 h−1); and elimination rate constant of G-ZDV, 2.27 h−1. On the basis of simulations with FDA and WHO dosing recommendations, the probabilities of observing efficient exposures (doses resulting in exposures of between 3 and 5 mg/liter · h) with less adverse events (doses resulting in exposures below 8.4 mg/liter · h) were higher when the FDA recommendations than when the WHO recommendations were followed. In order to improve the FDA recommendations, ZDV doses should be reconsidered for the weight band (WB) of 20 to 40 kg. The most appropriate doses should be decreased from 9 to 8 mg/kg of body weight twice a day (BID) for the WB from 20 to 29.9 kg and from 300 to 250 mg BID for the WB from 30 to 39.9 kg. The highest dose, 300 mg BID, should be started from body weights of 40 kg.
    Antimicrobial Agents and Chemotherapy 10/2013; 57(10). · 4.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B infection is best controlled by prevention rather than treatment, as chronic infection is usual once infected at a young age. Infant immune-prophylaxis is highly efficacious, although in the setting of high maternal viral load, breakthrough infection still occurs in almost 10 % of babies. Ante partum antiviral therapy for the purpose of preventing mother to child transmission in this group is important to consider. This article provides an up-to-date account of the available evidence of the safety and efficacy of ante partum antiviral therapy options and a management plan is proposed. Mothers with HBV infection and high viral load should have the opportunity to consider this evidence. Post-partum HBV flares are common but usually mild. It is unclear whether post partum flares are best ignored till they settle or if they represent an opportunity for intervention to increase the chance of HBV clearance.
    Current Hepatitis Reports 12/2012; 11(4).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For the first time, a population approach was used to describe abacavir pharmacokinetics in HIV infected pregnant and non-pregnant women. A total of 266 samples were obtained from 150 women. No covariate effect (age, bodyweight, pregnancy, gestational age) was found on abacavir pharmacokinetics. Thus, it seems not necessary to adapt ABC dosing regimen during pregnancy.
    Antimicrobial Agents and Chemotherapy 07/2014; · 4.45 Impact Factor

Full-text (2 Sources)

Available from
May 31, 2014